This Plain Language Summary of Publication article (PLSP) from Future Oncology examines two key studies (ELEVATE-RR and ASCEND) that evaluate acalabrutinib’s effectiveness compared to both standard chemotherapy and modern targeted therapies for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have previously received treatment for their blood cancer.

Visit the site using this link to read the article.

This PLSP is based on two articles called ‘Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results’ published in HemaSphere, and ‘Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial’ published in the Journal of Clinical Oncology.

Visit HemaSphere using the link to read the original article.

Visit ASCO Publications using the link to read the original article.